On June 12, 2025 Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported the presentation of AI/ML driven predictive computational research at upcoming international scientific conferences reflecting Compugen’s scientific capabilities in understanding complex cancer biology (Press release, Compugen, JUN 12, 2025, View Source [SID1234653860]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster details:

Conference: 2025 Annual Congress of the European Association for Cancer Research, June 16-19 Lisbon, Portugal
Poster number: EACR25-3113
Title: Prediction of immune evasion and immunotherapy resistance mechanisms associated with distinct TNBC subtypes
Presenting author: Amir Toporik, Computational Discovery, Compugen
Date of presentation: June 18, 2025

Conference: International Society for Computational Biology and European Conference on Computational Biology- Annual International Conference on Intelligent Systems for Molecular Biology, July 20-24, 2025, Liverpool, UK
Poster number: 947
Title: Computational prediction of TNBC tumor subtypes from an integrative single cell atlas elucidates immune evasion and immunotherapy resistance mechanisms
Presenting author: Itamar Borukhov, Ph.D., Computational Discovery, Compugen

Posters will be available in the publications section of Compugen’s website, www.cgen.com, following presentation.